## Epigenetic profiling of Italian patients identified methylation sites associated with

# hereditary Transthyretin amyloidosis

- 3 Antonella De Lillo, Gita A. Pathak, Flavio De Angelis, Marco Di Girolamo, Marco Luigetti, Marco Luigetti, Se
- 4 Mario Sabatelli, <sup>6,7</sup> Federico Perfetto, <sup>8</sup> Sabrina Frusconi, <sup>9</sup> Dario Manfellotto, <sup>4</sup> Maria Fuciarelli, <sup>1</sup> Renato
- 5 Polimanti<sup>2,3\*</sup>

1

2

6

17

23

- <sup>1</sup>Department of Biology, University of Rome Tor Vergata, Rome, Italy
- <sup>2</sup>Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA
- 9 <sup>3</sup>VA CT Healthcare Center, West Haven, CT, USA
- <sup>4</sup>Clinical Pathophysiology Center, Fatebenefratelli Foundation 'San Giovanni Calibita' Fatebenefratelli
- 11 Hospital, Rome, Italy
- <sup>5</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Rome, Italy
- <sup>6</sup>Università Cattolica del Sacro Cuore, Rome, Italy
- <sup>7</sup> 'Centro Clinico NEMO adulti', Rome, Italy
- <sup>8</sup>Regional Amyloid Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
- <sup>9</sup>Genetic Diagnostics Unit, Laboratory Department, Careggi University Hospital, Florence, Italy
- 18 \*Corresponding author:
- 19 Dr. Renato Polimanti. Department of Psychiatry, Yale University School of Medicine and VA CT
- Healthcare Center, VA CT 116A2, 950 Campbell Avenue, West Haven,
- 21 CT 06516, USA. Tel: +1 203 932 5711 x5745; Fax: +1 203 937-3897; E-mail:
- 22 renato.polimanti@yale.edu; ORCID: 0000-0003-0745-6046

### Abstract

25

Hereditary Transthyretin (TTR) Amyloidosis (hATTR) is a rare life-threatening disorder caused by 26 27 amyloidogenic coding mutations located in TTR gene. To understand the high phenotypic variability observed among carriers of TTR disease-causing mutations, we conducted an epigenome-wide association 28 29 study (EWAS) assessing more than 700,000 methylation sites and testing i) TTR coding mutation carriers vs. non-carriers, and ii) Val30Met (rs28933979) carriers vs. carriers of other TTR mutations. In the first 30 31 analysis, we observed a significant methylation change at cg09097335 site located in Beta-secretase 2 (BACE2) gene (beta =-0.60, p=6.26×10<sup>-8</sup>). This gene is involved in a protein interaction network enriched 32 for biological processes and molecular pathways related to amyloid-beta metabolism (Gene 33 Ontology:0050435, q=0.007), amyloid fiber formation (Reactome HSA-977225, q=0.008), and 34 Alzheimer's disease (KEGG hsa05010, q= $2.2 \times 10^{-4}$ ). Additionally, TTR and BACE2 share APP (Amyloid-35 36 beta precursor protein) as a validated protein interactor. In the second analysis, we observed that Val30Met carriers have a significant hypomethylation at cg13139646 site located in TTR exonic region 37 (beta=-2.18, p=3.34×10<sup>-11</sup>). A methylation quantitative trait locus analysis considering a 20 Kb region 38 39 including TTR coding and non-coding regions suggested that TTR coding variants (Ile68Leu, rs121918085; Ala120Ser, rs876658108; Gly6Ser, rs1800458) have independent effects on cg13139646 40 41 methylation, while no independent effect was observed for non-coding variants. In conclusion, we 42 provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of 43 hATTR, highlighting the role of epigenetic regulation in this rare disorder.

## Key words

44

45

46

47

hATTR, amyloidosis, Val30Met mutation, epigenetics, methylation, mQTL, modifier gene.

### **Background**

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Hereditary transthyretin amyloidosis (OMIM#105210) (hATTR) is a life-threatening disorder caused by transthyretin (TTR) misfolding and consequently amyloid fibril deposition in several tissues (e.g., peripheral nerves, heart, and gastrointestinal tract) (1, 2). This rare condition is characterized by extreme clinical heterogeneity including age of onset, penetrance, and clinical display (3-5). To date, more than 130 amyloidogenic mutations have been identified in the coding regions of the TTR gene, which are the cause of hATTR (6). The prevalence of hATTR is estimated to be approximately 1/100,000 (7). However, endemic areas of hATTR were identified in Portugal and Sweden (4, 5). Although both of these regions are affected by the same amyloidogenic mutation, Val30Met (rs28933979), their penetrance and age of onset are different: early age of onset and high penetrance in Portugal (4, 5, 8, 9); late age of onset and low penetrance in Sweden and in non-endemic countries (3, 10, 11). It has been hypothesized that hATTR phenotypic heterogeneity is due to the contribution of genetic and non-genetic factors involved in the complex genotype-phenotype correlation observed (12-18). Recent data strongly support the role of non-coding regulatory variation on TTR gene expression, as one of the mechanisms affecting the phenotypic manifestations observed in carriers of TTR amyloidogenic mutations (19-22). Among genomic regulatory features, epigenetic modifications are demonstrated to be key mechanisms in modulating a wide range of molecular functions and potential targets to develop novel treatments (23-25). Of several epigenetic modifications, DNA methylation is the most studied with respect to human traits and diseases (23). With respect to monogenic disorders, methylation studies investigated the role of epigenetic changes involved in the phenotypic expression observed among carriers of disease-causing mutations (26-28). Although epigenetic modifications have the potential to be involved in hATTR pathogenic mechanisms, to our knowledge no study explored methylation changes of patients affected by this life-threatening disease. In the present study, we conducted an epigenome-wide association study (EWAS) to identify DNA methylation associated with hATTR, investigating 48 carriers of TTR amyloidogenic mutations and 32 controls. We also tested whether there are significant epigenetic changes among carriers of different amyloidogenic mutations. The results obtained showed: i) hATTR confirmed

cases have significant methylation changes in modifier genes potentially involved in amyloidogenic processes; ii) carriers of Val30Met mutation showed a significant hypomethylation in *TTR* gene when compared to the carriers of other *TTR* amyloidogenic mutations.

#### Results

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

The epigenome-wide analysis testing the differences between 48 carriers of TTR amyloidogenic mutatinos and 32 controls identified a significant methylation site surviving false discovery rate multiple testing correction (FDR q<0.05) at the cg09097335 site located in Beta-secretase 2 (BACE2) gene body (beta = -0.60,  $p=6.26\times10^{-8}$ , FDR q=0.044; Table 1). Carriers of TTR amyloidogenic mutations showed a significant hypomethylation when compared to controls (Figure 1). To characterize the function of BACE2 protein product, we investigated interactive proteins based on multiple experimental and computational evidence, identifying five candidates with medium-to-highest interaction confidence (Figure 2). These include FYN (FYN proto-oncogene, Src family tyrosine kinase; interaction score=0.809), BACE1 (Beta-secretase 1; interaction score=0.804), APP (amyloid-beta precursor protein; interaction score=0.430), IGHV3-11 (immunoglobulin heavy variable 3-11; interaction score=0.412), and ENSG00000259680 (uncharacterized protein similar to an immunoglobulin heavy variable 3/OR16 gene; interaction score=0.412). Among them, TTR showed the highest interaction with APP protein (interaction score=0.936). BACE2 protein interactive network (Figure 2) showed functional enrichments for several biological processes and molecular pathways (Table 2). Among the enrichments directly related to BACE2 function, we observed: Alzheimer's disease (KEGG hsa05010, FDR q=2.2×10<sup>-4</sup>) related to the interaction of BACE2 with APP and BACE1; membrane protein ectodomain proteolysis (GO:0006509, FDR q=0.007) and amyloid-beta metabolic process (GO:0050435, FDR q=0.007) related to BACE2-BACE1 interaction; protein metabolic process (GO:0019538, FDR q=0.043) related to the interaction of BACE with APP, BACE1, FYN, and IGHV3-11. The interactions of other proteins within BACE2 interactive network also highlighted amyloid-related functional enrichments: amyloid fiber formation (Reactome HSA-977225, FDR q=0.008) and response to amyloid-beta (GO:1904645, FDR q=0.009) related to the interaction of APP with BACE1 and FYN, respectively.

Comparing the epigenetic profile of Val30Met carriers (N=33) vs. that of carriers of other TTR mutations 101 102 (N=15), we identified a methylation site surviving the epigenome-wide multiple testing correction (Table 1). A CpG site located in the second exon of TTR gene (cg13139646) showed a significant 103 hypomethylation in Val30Met carriers when compared with carriers of other TTR mutations (beta= -2.18, 104  $p=3.34\times10^{-11}$ , FDR  $q=2.40\times10^{-5}$ ; Figure 3). To better understand whether the association of Val30Met 105 106 with cg13139646 methylation is due to the effect of other regulatory variants in LD with this 107 amyloidogenic mutation, we conducted a methylation quantitative trait locus (mQTL) analysis in a subset 108 (N=15) of hATTR patients with complete sequencing of TTR coding and non-coding regions. Val30Met confirmed the strongest association with cg13139646 methylation (beta=-1.07, p=0.023; Additional File 109 110 1). None of the variants in LD with Val30Met showed stronger evidence of association (Additional File 2). Among the variants tested, Ile68Leu mutation was also associated with cg13139646 methylation: 111 112 Ile68Leu carriers are hypermethylated when compared to the carriers of other mutations (beta=1.71, p= 113 0.045; Additional File 1). Suggestive evidences of associations were also observed for other TTR coding 114 variants: Ala120Ser (beta=1.62, p=0.058) and Gly6Ser (rs1800458, beta=-1.14, p=0.069). These coding variants are not in LD each other (LD  $r^2$ =0; Additional File 2), indicating each association on cg13139646 115 116 methylation is independent. However, non-coding variants located in the upstream and downstream regions of TTR gene showed a perfect LD (r<sup>2</sup>=1; Additional File 2) with Ile68Leu (LD with upstream 117 variant rs72922940) and Ala120Ser (LD with downstream variant rs76431866 and upstream variants 118 119 ss1360573709 and ss1360573712). Finally, we explored whether the epigenetic changes identified are associated with symptoms reported by 120 121 patients affected by hATTR. None of the associations reached a statistical significance (Additional File 122 3).

### Discussion

123

124

125

126

127

hATTR is a rare multi-organ disorder caused by TTR misfolding and consequently amyloid deposition in several tissues (29). This life-threatening condition is characterized by high clinical heterogeneity with respect to age of onset, penetrance, and phenotypic manifestation (1-10, 29). Although *TTR* 

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

amyloidogenic mutations are the cause of TTR misfolding, non-coding variation and modifier genes are hypothesized to be involved in wide variability of phenotypic manifestations observed in carriers of TTR disease-causing mutations (12, 15, 17-22). Epigenetic modifications (e.g., DNA methylation changes) could also play an important role in the molecular network regulating the hATTR amyloidogenic process (25). To explore this hypothesis, we conducted an EWAS investigating more than 700,000 methylation sites in 48 carriers of TTR amyloidogenic mutations and 32 non-carriers. A CpG site (cg09097335) located in BACE2 gene was significantly hypomethylated in carriers when compared to non-carriers. This gene encodes Beta-secretase 2, a protein mainly known for its role in cleaving APP protein in amyloidbeta, which is a key factor involved in AD pathogenesis (30-32). Several studies showed that, unlike BACE1 that is the primary  $\beta$ -secretase protein cleaving APP to amyloid-beta, BACE2 is poorly expressed in the brain and its cleaving ability increases following an inflammatory response (33). APP processing occurs via three proteolytic cleavages caused by α- β- and γ-secretase (34). In nonamyloidogenic processes, α- and γ-secretases lead to the production of a smaller P3 fragment and APP intracellular domain, while, in the amyloidogenic pathway,  $\beta$ -secretase and  $\gamma$ -secretase produce amyloidbeta (34-38). Our results also showed a high-confidence interaction between APP and TTR. Numerous studies explored the interactions between these two amyloidogenic proteins, displaying a relevant biological role of TTR in amyloid-beta aggregation and clearance in AD patients (39-43). Specifically, altered TTR stability seems to reduce the clearance of amyloid-beta, increasing its toxicity in the brain (39-41). Metal ions and interaction with other proteins could also affect TTR stability (39). Interestingly, a significant association between amyloid-beta levels and AD was identified in AD patients with TTR Val30Met (39, 43). A putative amyloidogenic role of amyloid-beta in hATTR was also identified in a post-mortem analysis of a Val30Met carrier where both TTR and amyloid-beta were deposited in the cerebral leptomeningeal and cortical blood vessel walls with a part of the vessel wall occupied by a combination of TTR and amyloid-beta aberrant proteins (42). These previous findings strongly indicate an interplay between the pathogenic mechanisms involved in hATTR and AD. Our epigenome-wide study identified BACE2 as a potential key factor in this interaction. As previously discussed, BACE2 protein plays a minor role in APP cleaving in the brain (32, 33), while its activity increases in peripheral

tissues under inflammatory response (33). Under this scenario, we hypothesize that the methylation change observed in the carriers of TTR mutations is due to BACE2 response to the inflammation induced by TTR amyloidogenic process in peripheral tissues (44). In the epigenome-wide analysis testing carriers of TTR Val30Met vs. carriers of other TTR amyloidogenic mutations, we identified a CpG site, cg13139646, located in the second exon of TTR gene. Follow-up analyses showed that the methylation at this CpG site is independently associated with other TTR coding variants but not by non-coding variants. It is known that methylation profile differs between exonic and intronic regions (45). Although the transcriptional modulation is strongly regulated by the methylation of promoter regions, hypomethylation in exonic regions is associated with transcriptional upregulation while hypermethylation could promote the transcriptional silencing (45, 46). As mentioned, TTR amyloid accumulation causes tissue damage leading to inflammatory response activation, increasing reactive oxygen species (ROS) production and TTR oxidation (47). Val30Met mutation has been associated with increased S-nitrosylation during the amyloidogenic process, leading to the production of nitric oxide (NO), which increases the formation of amyloid fibrils (47). The association of Val30Met with these complex biochemical changes could explain the hypomethylation of cg13139646 in the carriers as a response to the specific amyloidogenic process induced by this mutation. We could also speculate that Val30Met and its induced biochemical changes are part of a feedback loop also including methylation changes and transcriptomic regulation of TTR gene. The independent effects observed with respect to other TTR coding variants could be related to the specific amyloidogenic process induced by them. We also observed suggestive evidence of association between cg13139646 methylation and Gly6Ser, a benign TTR coding variant. However, Levine and Bland (48) further explored the effect of this nonamyloidogenic mutation in individuals with autonomic and small fiber neuropathy, reporting a potential role of Gly6ser in the predisposition to neurodegenerative diseases.

#### Conclusions

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

Our study provided novel insights regarding the pathogenesis of hATTR, supporting the involvement of methylation changes in the amyloidogenic process induced by *TTR* disease-causing mutations. Further

studies will be needed to characterize specific mechanisms underlying the epigenetic associations, in particular, the potential role of amyloid-beta metabolic process and inflammatory response. The understanding of how methylation changes modulate the penetrance and the severity of *TTR* mutations could lead to the identification of novel targets to develop treatments and screening tools for the carriers.

## Methods

Thirty-eight symptomatic patients and 10 asymptomatic *TTR* mutations carriers were recruited from three Italian centers for the treatment of systemic amyloidosis: "San Giovanni Calibita" Fatebenefratelli Hospital, Isola Tiberina – Rome, Fondazione Policlinico Universitario "A. Gemelli" – Rome and Careggi University Hospital – Florence (16-20). Thirty-two controls were recruited by the Department of Biology – University of Rome "Tor Vergata" (Table 3).

hATTR diagnosis was based on the presence of clinical signs and symptoms and the presence of an amyloidogenic mutation on *TTR* gene. The coding mutations identified include: Val30Met (rs28933979), Phe64Leu (rs121918091), Ile68Leu (rs121918085), Ala120Ser (rs876658108), and Val122lle (rs76992529). One hATTR patient is a carrier of a mutation (rs36204272) in an intronic region with a putative clinical impact (48). Information regarding the organ involvements was collected for each patient: peripheral and nerve involvement (nerve conduction study); cardiac involvement (electrocardiographic and echocardiography anomalies); gastrointestinal involvement (gastric paresis, stypsis, or diarrhea); autonomic neurological involvement (orthostatic hypotension and urinary incontinence); ocular involvement (vitreous opacities): and carpal tunnel syndrome (median nerve decompression) (11, 49-51). The present study was approved under the protocol 39/18 by the Comitato

### DNA methylation analysis

DNA was extracted using the phenol/chloroform protocol (52) and purified through Amicon Ultra-0.5 mL Centrifugal Filters (EMD Millipore) to achieve a DNA concentration of 100 ng/μL. DNA concentration was checked via NanoDrop technology (ND-1000, Thermofisher Scientific) and Qubit Quantitation

Etico Indipendente, Fondazione Policlinico Tor Vergata – Rome, Italy.

technology (High Accuracy & Sensitivity, Thermofisher). DNA methylation analysis was executed in two phases: the EZ DNA Methylation kit (Zymo Research) was used to perform sodium bisulfite conversion; the Illumina Infinium Methylation EPIC Chip (with over 850,000 methylation sites; Illumina Inc.) was used to quantify DNA methylation according to the standard Illumina protocol. The methylation array analysis was performed at the Connecting bio-research and Industry Center, Trieste – Italy.

### Preprocessing, quality control, and normalization

The raw signal intensity files were processed and cleaned using R 3.6 with ChAMP package (53). The ratio of methylated and unmethylated intensities from idat files was converted into beta values for further processing. The probes failing thresholds on detection value, bead count, sites near SNPs, probes that align to multiple positions, sex chromosomes and outliers were removed. None of the samples failed quality control. The remaining 718,509 probes for 80 individuals were normalized with BMIQ. Batch effects were assessed using singular vector decomposition and corrected with ComBat method (54). The genomic lambda of the case-control association was 1.03, calculated using QQPerm package (https://cran.r-project.org/web/packages/QQperm/index.html).

## Blood cell type composition, genetic variability estimation, and smoking prediction

References-based method was employed to adjust for the heterogeneity due to the cell type composition of the whole blood samples investigated (55). This method uses specific DNA methylation signatures derived from purified whole blood cell-type as biomarkers of cell identity, to correct beta value dataset. Cell proportions for five cell-types (B cells, granulocytes, monocytes, natural killer cells, and T cells) were detected, and a linear regression was applied (53, 55).

To account for the genetic variability among the samples investigated, principal components (PCs) were calculate using the method proposed by Barfield, Almli (56). This approach allowed us to compute PCs based on CpGs selected for their proximity to SNPs. The data obtained can be used to adjust for population stratification in DNA methylation studies when genome-wide SNP data are unavailable (56).

Cigarette smoke has a very large effect on DNA methylation profile, triggering alteration at multiple CpGs (57). Consequently, smoking status needs to be considered as a potential confounder in epigenetic association studies. EpiSmokEr package was used to classify the smoking status of each participant on the basis of their epigenetic profile (58). Briefly, EpiSmoker is a prediction tool that provides smoking probabilities for each individual (never-smoker, former-smoker, and current smoker) using a set of 121 informative CpG sites (57).

## Data analysis

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

We conducted two epigenome-wide analyses testing 718,509 methylation sites. First, we investigated the methylation changes between 48 cases (i.e., carriers of a TTR amyloidogenic mutation) and 32 controls. Second, we analyzed the epigenetic differences between Val30Met carriers (the most frequent mutation in our cohort; N= 33) and the carriers of other TTR mutations (N= 15). In both association analyses, we implemented a linear regression analysis including cell composition proportions, top three genetic PCs, epigenetically-determined smoking status, age, and sex as covariates. FDR method was applied to adjust the results for multiple testing (59) and the q-value < 0.05 was considered as the significance threshold. STRING v.11.0 (60) was used to identify protein interaction with the loci identified, considering experiments, co-expression, co-occurrence, gene fusion, and neighborhood as active sources and an interaction score higher than 0.4 (medium confidence). The protein interaction network was investigated further conducting functional enrichments association related to the protein-protein interactions identified considering Gene Ontologies (61) for biological processes and molecular pathways available from Reactome Database (62) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (63). FDR (q-value < 0.05) was applied to account for multiple testing assuming the whole genome as the statistical background. To detect associations between genetic variants and methylation changes in sites located in the chromosomal region of TTR gene, we investigated the association of epigenetic changes with genetic variability of 15 hATTR affected individuals analyzed previously (20). Plink 1.09 (64) was used to perform association analysis. Haploview (65) was used to determine linkage disequilibrium (LD) among tested variants.

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

List of abbreviations AD, Alzheimer disease; APP, amyloid beta precursor protein; hATTR, Hereditary transthyretin amyloidosis; BACE1, beta-secretase 1; BACE2, beta-secretase 2; EWAS, epigenome-wide association studies; FDR, false discovery rate; FYN, FYN proto-oncogene, Src family tyrosine kinase; IGHV3-11, immunoglobulin heavy variable 3-11; LD, linkage disequilibrium; mQTL, methylation quantitative trait loci; NO, nitric oxide; ROS, reactive oxygen species; TTR, transthyretin. **Declarations** Ethics approval and consent to participate This study was approved under the protocol 39/18 by the Comitato Etico Indipendente, Fondazione Policlinico Tor Vergata – Rome, Italy. Informed consent was obtained from each participant involved. Availability of data and materials Data supporting the findings of this study are available within this article and its additional files. **Competing interests** Drs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest. **Funding** This study was supported by an Investigator-Initiated Research from Pfizer Inc. to the University of Rome Tor Vergata. Pfizer Inc. had no role in the study design, data analysis, and results interpretation of the present study.

### **Authors' contributions**

288

289

290

295

296

298

299

- ADL, FDA, MF, and RP were involved in study design. MDG, ML, MS, FP, SF, and DM conducted the
- recruitment and assessment of the participants. ADL, GAP, and RP carried out the statistical analysis. All
- 293 authors were involved in the interpretation of the results. ADL and RP wrote the first draft of the
- 294 manuscript and all authors contributed to the final version of the manuscript.

## Acknowledgements

We thank the participants involved in this study and their caregivers.

### Bibliography

- Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem. 2012;19(15):2324-42.
- 302 2. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 303 2014;3:19.
- 304 3. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V.
- Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181-6.
- 4. Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid. 2012;19 Suppl 1:71-2.
- 308 5. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of
- transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European
- 310 network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin
- 311 Neurol. 2016;29 Suppl 1:S3-S13.
- 6. Conceicao I, Damy T, Romero M, Galan L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR
- amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid.
- 314 2019;26(1):3-9.
- 315 7. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-
- related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
- 8. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic
- polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med
- 319 Genet. 1995;60(6):512-21.
- 9. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, et al.
- 321 Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.
- 322 J Med Genet. 2003;40(11):e120.
- 323 10. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic
- polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered.
- 325 1993;43(5):288-94.
- 11. Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, et al. TTR-related
- amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.
- 328 Neurol Sci. 2013;34(7):1057-63.


- 12. Alves-Ferreira M, Coelho T, Santos D, Sequeiros J, Alonso I, Sousa A, et al. A Trans-acting 329
- 330 Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal. Mol
- 331 Neurobiol. 2018;55(5):3676-83.
- 332 Bonaiti B, Olsson M, Hellman U, Suhr O, Bonaiti-Pellie C, Plante-Bordeneuve V. TTR familial
- 333 amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin
- 334 difference in penetrance? Eur J Hum Genet. 2010;18(8):948-52.
- Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Mendonca D, Alonso I, et al. Variants in 335
- 336 RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J
- 337 Hum Genet. 2016;24(5):756-60.
- 338 Soares ML, Coelho T, Sousa A, Batalov S, Conceicao I, Sales-Luis ML, et al. Susceptibility and
- 339 modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene
- 340 disease. Hum Mol Genet. 2005:14(4):543-53.
- 341 Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto L, Mauro A, et al. Most recent
- 342 common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-
- 343 phenotype correlation. Amyloid. 2015;22(2):73-8.
- Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the 344
- 345 transthyretin gene among human populations and its correlation with amyloidosis phenotypes. Amyloid.
- 346 2013;20(4):256-62.
- 347 18. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. In silico analysis of TTR gene (coding
- 348 and non-coding regions, and interactive network) and its implications in transthyretin-related
- 349 amyloidosis. Amyloid. 2014;21(3):154-62.
- Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto LG, Mazzeo A, et al. Population 350
- 351 diversity of the genetically determined TTR expression in human tissues and its implications in TTR
- 352 amyloidosis. BMC Genomics. 2017;18(1):254.
- Iorio A, De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Sabatelli M, et al. Non-coding 353
- 354 variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet. 2017;25(9):1055-
- 355 60.
- 356 De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Frusconi S, Manfellotto D, et al. Phenome-
- 357 wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the
- 358 genetics of hereditary and wildtype transthyretin amyloidoses. Hum Genet. 2019;138(11-12):1331-40.
- 359 Polimanti R, Nunez YZ, Gelernter J. Increased Risk of Multiple Outpatient Surgeries in African-
- 360 American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. J Clin Med. 2019;8(2).
- 361
- 362 Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N Engl J
- 363 Med. 2018;378(14):1323-34.
- Yan H, Tian S, Slager SL, Sun Z, Ordog T. Genome-Wide Epigenetic Studies in Human Disease: 364
- 365 A Primer on -Omic Technologies. Am J Epidemiol. 2016;183(2):96-109.
- 366 Szymczak S, Dose J, Torres GG, Heinsen FA, Venkatesh G, Datlinger P, et al. DNA methylation
- 367 QTL analysis identifies new regulators of human longevity. Hum Mol Genet. 2020.
- 368 Clissold RL, Ashfield B, Burrage J, Hannon E, Bingham C, Mill J, et al. Genome-wide
- 369 methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion. Clin
- Epigenetics. 2018;10(1):97. 370
- 371 Guay SP, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L. ABCA1 gene promoter
- DNA methylation is associated with HDL particle profile and coronary artery disease in familial 372
- hypercholesterolemia. Epigenetics. 2012;7(5):464-72. 373
- Magalhaes M, Rivals I, Claustres M, Varilh J, Thomasset M, Bergougnoux A, et al. DNA 374
- 375 methylation at modifier genes of lung disease severity is altered in cystic fibrosis. Clin Epigenetics.
- 2017;9:19. 376
- Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of 377
- 378 Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving
- 379 Patient Care. Ther Clin Risk Manag. 2020;16:109-23.
- 380 Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol
- 381 Neurodegener. 2011;6(1):27.

- 382 31. Sassi C, Ridge PG, Nalls MA, Gibbs R, Ding J, Lupton MK, et al. Influence of Coding Variability
- in APP-Abeta Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One. 2016;11(6):e0150079.
- 32. Wang Z, Xu Q, Cai F, Liu X, Wu Y, Song W. BACE2, a conditional beta-secretase, contributes to
- Alzheimer's disease pathogenesis. JCI Insight. 2019;4(1).
- 386 33. Voytyuk I, Mueller SA, Herber J, Snellinx A, Moechars D, van Loo G, et al. BACE2 distribution
- in major brain cell types and identification of novel substrates. Life Sci Alliance. 2018;1(1):e201800026.
- 388 34. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain.
- 389 2011;4:3.
- 35. Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, et al. A rare loss-of-function variant of
- ADAM17 is associated with late-onset familial Alzheimer disease. Mol Psychiatry. 2020;25(3):629-39.
- 392 36. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense
- mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron.
- 394 2013;80(2):385-401.
- 395 37. Tambini MD, Norris KA, D'Adamio L. Opposite changes in APP processing and human Abeta
- levels in rats carrying either a protective or a pathogenic APP mutation. Elife. 2020;9.
- 397 38. Durrant CS, Ruscher K, Sheppard O, Coleman MP, Ozen I. Beta secretase 1-dependent amyloid
- 398 precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. Cell
- 399 Death Dis. 2020;11(2):98.
- 400 39. Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta
- amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease. CNS Neurosci Ther.
- 402 2017;23(7):605-19.
- 40. Costa R, Goncalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide--impact on
- 404 A-Beta fibrillogenesis and toxicity. FEBS Lett. 2008;582(6):936-42.
- 40.5 41. Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin
- monomers and tetramers. Biochemistry. 2010;49(38):8276-89.
- 407 42. Sakai K, Asakawa M, Takahashi R, Ishida C, Nakamura R, Hamaguchi T, et al. Coexistence of
- 408 transthyretin- and Abeta-type cerebral amyloid angiopathy in a patient with hereditary transthyretin
- 409 V30M amyloidosis. J Neurol Sci. 2017;381:144-6.
- 410 43. Xiang Q, Bi R, Xu M, Zhang DF, Tan L, Zhang C, et al. Rare Genetic Variants of the
- Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese. Mol Neurobiol.
- 412 2017;54(7):5192-200.
- 413 44. Azevedo EP, Guimaraes-Costa AB, Bandeira-Melo C, Chimelli L, Waddington-Cruz M, Saraiva
- EM, et al. Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol.
- 415 2019;19(1):146.
- 416 45. Chuang TJ, Chen FC, Chen YZ. Position-dependent correlations between DNA methylation and
- the evolutionary rates of mammalian coding exons. Proc Natl Acad Sci U S A. 2012;109(39):15841-6.
- 418 46. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, et al. DNA methylation of the first
- exon is tightly linked to transcriptional silencing. PLoS One. 2011;6(1):e14524.
- 420 47. Sharma M, Khan S, Rahman S, Singh LR. The Extracellular Protein, Transthyretin Is an Oxidative
- 421 Stress Biomarker. Front Physiol. 2019;10:5.
- 422 48. Levine TD, Bland RJ. Incidence of nonamyloidogenic mutations in the transthyretin gene in
- patients with autonomic and small fiber neuropathy. Muscle Nerve. 2018;57(1):140-2.
- 424 49. Russo M, Mazzeo A, Stancanelli C, Di Leo R, Gentile L, Di Bella G, et al. Transthyretin-related
- familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late
- onset. J Peripher Nerv Syst. 2012;17(4):385-90.
- 427 50. Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, et al. Transthyretin-Related
- 428 Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic
- 429 Area. J Neuromuscul Dis. 2015;2(s2):S39-S48.
- 430 51. Gagliardi C, Perfetto F, Lorenzini M, Ferlini A, Salvi F, Milandri A, et al. Phenotypic profile of
- 431 Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. Eur J Heart Fail.
- 432 2018;20(10):1417-25.
- 433 52. Budowle B, Moretti, T., Smith, J., and Dizinno, J. DNA typing protocols: Molecular Biology and
- Forensic analysis. A Bio Techniques® Books Publications (Natick, MA: Eaton Publishing). 2000.


- 435 53. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation
- analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982-4.
- 437 54. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
- empirical Bayes methods. Biostatistics. 2007;8(1):118-27.
- 439 55. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al.
- DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics.
- 441 2012;13:86.
- 442 56. Barfield RT, Almli LM, Kilaru V, Smith AK, Mercer KB, Duncan R, et al. Accounting for
- population stratification in DNA methylation studies. Genet Epidemiol. 2014;38(3):231-41.
- 444 57. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking
- leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812.
- 446 58. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to
- determine smoking status from DNA methylation data. Epigenomics. 2019;11(13):1469-86.
- 448 59. Benjamini Y, Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful
- 449 Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological).
- 450 1995;57:289-300.

465


- 451 60. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:
- 452 protein-protein association networks with increased coverage, supporting functional discovery in genome-
- wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D13.
- 454 61. The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic
- 455 Acids Res. 2019;47(D1):D330-D8.
- 456 62. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway
- knowledgebase. Nucleic Acids Res. 2020;48(D1):D498-D503.
- 458 63. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on
- genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353-D61.
- 460 64. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
- rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
- 462 65. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype
- 463 maps. Bioinformatics. 2005;21(2):263-5.



**Figure 1:** Methylation levels of cg09097696 site in carriers vs. non-carriers of amylodogenic mutations.



**Figure 2:** BACE2 protein interaction network. Node colour of the protein is proportional to the interaction score with BACE2. Connector shade and width are proportional to the interaction confidence (highest, high, and medium).



**Figure 3:** Methylation levels of cg13139646 site in Val30Met carriers vs. carriers of other TTR amyloidogenic mutations.

**Table 1:** Significant methylation sites identified in the case-control analysis and in the Val30Met analysis. Information about cg probe (cgID), chromosome localization (chr), position (pos), CpG context, mapped gene, gene region, effect (beta), p value (p-value) and false discovery rate (FDR) q value are reported.

.91

.92

.93

.94

.95

.96

.97

.98

.99

100

01

02

03

04

05

06

i07

i08

cgID	chr	pos	s CpG Mapped	Mapped	Gene	beta	p-value	FDR		
			context	gene	region					
Cases vs Controls										
cg09097335	21	42597642	Open Sea	BACE2	Body	-0.60	$6.26 \times 10^{-8}$	0.044		
Val30Met vs non-Val30Met										
cg13139646	18	29172936	Open Sea	TTR	Body	-2.18	$2.14 \times 10^{-7}$	7.86×10 <sup>-5</sup>		

Table 2: Enrichments for gene ontologies (GO) of biological processes and for Reactome and KEGG molecular pathways (HSA and hsa, respectively).

ID	Description	Proteins	False Discovery Rate
hsa05010	Alzheimer's disease	APP,BACE1,BACE2	2.2E-04
HSA-2029481	FCGR activation	FYN,IGHV3-11	7.9E-04
HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	FYN,IGHV3-11	7.9E-04
HSA-983695	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	FYN,IGHV3-11	0.002
GO:0006509	membrane protein ectodomain proteolysis	BACE1,BACE2	0.007
GO:0050435	amyloid-beta metabolic process	BACE1,BACE2	0.007
GO:1902950	regulation of dendritic spine maintenance	APP,FYN	0.007
HSA-977225	Amyloid fiber formation	APP,BACE1	0.008
GO:1904645	response to amyloid-beta	APP,FYN	0.009
HSA-109582	Hemostasis	APP,FYN,IGHV3-11	0.010
GO:0106027	neuron projection organization	APP,FYN	0.010
GO:1900449	regulation of glutamate receptor signaling pathway	APP,FYN	0.010
HSA-202733	Cell surface interactions at the vascular wall	FYN,IGHV3-11	0.010
GO:0061098	positive regulation of protein tyrosine kinase activity	APP,FYN	0.017
GO:1903201	regulation of oxidative stress-induced cell death	APP,FYN	0.017
GO:0006897	Endocytosis	APP,FYN,IGHV3-11	0.018
GO:0007631	feeding behavior	APP,FYN	0.018
GO:0016358	dendrite development	APP,FYN	0.018
GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	FYN,IGHV3-11	0.018
GO:1901216	positive regulation of neuron death	APP,FYN	0.018
GO:1903426	regulation of reactive oxygen species biosynthetic process	APP,FYN	0.018
GO:1900180	regulation of protein localization to nucleus	APP,FYN	0.020
GO:0007612	Learning	APP,FYN	0.027
GO:0031347	regulation of defense response	APP,FYN,IGHV3-11	0.027
GO:2001056	positive regulation of cysteine-type endopeptidase activity	APP,FYN	0.027
GO:0030162	regulation of proteolysis	APP,FYN,IGHV3-11	0.031
GO:0051897	positive regulation of protein kinase B signaling	APP,FYN	0.031
GO:2000377	regulation of reactive oxygen species metabolic process	APP,FYN	0.031

HSA-168249	Innate Immune System	APP,FYN,IGHV3-11	0.032
HSA-76002	Platelet activation, signaling and aggregation	APP,FYN	0.032
GO:0050808	synapse organization	APP,FYN	0.034
GO:1901215	negative regulation of neuron death	APP,FYN	0.034
GO:0002684	positive regulation of immune system process	APP,FYN,IGHV3-11	0.037
GO:0050776	regulation of immune response	APP,FYN,IGHV3-11	0.037
GO:0002252	immune effector process	APP,FYN,IGHV3-11	0.041
GO:0007411	axon guidance	APP,FYN	0.041
GO:0019538	protein metabolic process	APP,BACE1,BACE2,FYN,IGHV3-11	0.043
GO:0006959	humoral immune response	APP,IGHV3-11	0.045

Table 3: Description of the study population. Information about TTR amyloidogenic mutations, sex, age, epigenetically-determined smoking status (never smoker, NS; former smoker, FS; current smoker, CS), and epigenetically-estimated ranges of T cells (CD8T and CD4T), Natural Killer cells (NK), B cells, monocytes (Mono) and granulocytes (Gran) are reported.

TTR	N	Sex	Age Median	Sr	moking	,	CD8T Median	an CD4T Median	NK Median	B cell Median	Mono Median	Gran Median <sub>⊕</sub>
Mutation	1₹	Female (%)	(Min-Max)	NS	FS	CS	(Min –Max)	(Min –Max)	(Min –Max)	(Min –Max)	(Min –Max)	$(Min - Max) \stackrel{\circ}{\Box}$
Cases												
Val30Met	33	10 (30)	65 (31-88)	1	23	9	$0.033 \\ (-3.24 \times 10^{-20} - 0.131)$	$0.118 \\ (1.1 \times 10^{-2} - 0.21)$	$0.033 \\ (-3.81 \times 10^{-19} - 0.127)$	$1.52 \times 10^{-3}$ (-5.55×10 <sup>-19</sup> – 0.066)	0.082 (0.038 – 0.147)	0.634 7 (0.551 – 0.824)
Phe64Leu	8	1 (12)	70 (48-75)	0	4	4	$4.02 \times 10^{-3} $ $(1.07 \times 10^{-18} - 1.112)$	$0.127 \\ (6.9 \times 10^{-2} - 0.228)$	$0.014 \\ (1.96 \times 10^{-20} - 0.099)$	$3.13 \times 10^{-3}$ (-2.17×10 <sup>-19</sup> – 0.021)	0.085 (0.057 – 0.107)	0.65 ≥ <u>≤</u> (0.46 – 0.70 <u>4</u> ) <del>p</del> .
Ala120Ser	2	2 (100)	67-68	0	2	0	$-3.34 \times 10^{-20} - 0$	0.068 - 0.11	$8.1 \times 10^{-3} - 1.28 \times 10^{-1}$	$0-5.1\times10^{-3}$	0.092 - 0.11	0.56 – 0.74
Ile68Leu	3	0	53 (30-62)	0	0	3	0	0.142 (0.07 – 0.16)	0.038 (0.013 – 0.041)	$4.4 \times 10^{-3} $ $(3.8 \times 10^{-3} - 5.1 \times 10^{-3})$	0.083 (0.096 – 0.147)	0.59 author/fund (0.603 – 0.76) ved.
Val122Ile	1	0	80	0	0	1	0	0.23	0.042	0.005	0.071	0.55 8
rs36204272*	1	0	65	0	1	0	0.069	0.14	0.052	0.006	0.129	0.505
Controls  Controls  0.014  0.092  0.571												
_	32	19 (59)	37 (20-76)	0	27	5	$0.015 \\ (8.45 \times 10^{-19} - 0.13)$	$0.16 \\ (0.045 - 0.34)$	$0.044 \\ (-2.68 \times 10^{-19} - 0.18)$	$0.014 \\ (1.08 \times 10^{-19} - 0.091)$	$0.092 \\ (0.051 - 0.13)$	0.571 % has (0.41 – 0.7)

125

26

27

28

<sup>129</sup> \*non-coding variant of uncertain clinical impact